Mission Therapeutics
Total Raised
$197.18MInvestors Count
16Deal Terms
2Funding, Valuation & Revenue
12 Fundings
Mission Therapeutics has raised $197.18M over 12 rounds.
Mission Therapeutics's latest funding round was a Series E - II for $13.3M on October 15, 2025.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
10/15/2025 | Series E - II | $13.3M | 3 | |||
7/2/2024 | Grant - IV | $5.2M | 2 | |||
3/14/2024 | Series E | $32.24M | 5 | |||
10/14/2021 | Grant - III | |||||
7/6/2020 | Series D |
Date | 10/15/2025 | 7/2/2024 | 3/14/2024 | 10/14/2021 | 7/6/2020 |
|---|---|---|---|---|---|
Round | Series E - II | Grant - IV | Series E | Grant - III | Series D |
Amount | $13.3M | $5.2M | $32.24M | ||
Investors | |||||
Valuation | |||||
Revenue | |||||
Sources | 3 | 2 | 5 |
Mission Therapeutics Deal Terms
2 Deal Terms
Mission Therapeutics's deal structure is available for 2 funding rounds, including their Series B from November 18, 2013.
Round | Series B | Series A |
|---|---|---|
Funding Date | ||
Pre-Money Valuation | ||
Post-Money Valuation | ||
Amount Raised | ||
Shares Authorized | ||
Issuance Price | ||
Dividend Rate | ||
Liquidation Preferences | ||
Liquidation Price | ||
Participation | ||
Conversion Price | ||
Anti Dilution | ||
General Voting | ||
Board Voting | ||
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series B | |||||||||||||||
Series A |
Mission Therapeutics Investors
16 Investors
Mission Therapeutics has 16 investors. SR One invested in Mission Therapeutics's Series E - II funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
8/27/2011 | 10/15/2025 | 6 Series A, Series B (2013), Series C (2016), Series D (2020), Series E (2024), Series E - II (2025) | Venture Capital | Pennsylvania | ||
8/27/2011 | 10/15/2025 | 6 Series A, Series B (2013), Series C (2016), Series D (2020), Series E (2024), Series E - II (2025) | Corporate Venture | Switzerland | ||
8/27/2011 | 10/15/2025 | 6 Series A, Series B (2013), Series C (2016), Series D (2020), Series E (2024), Series E - II (2025) | Venture Capital | France | ||
Corporate Venture | New York | |||||
Venture Capital | United Kingdom |
First funding | 8/27/2011 | 8/27/2011 | 8/27/2011 | ||
|---|---|---|---|---|---|
Last Funding | 10/15/2025 | 10/15/2025 | 10/15/2025 | ||
Investor | |||||
Rounds | 6 Series A, Series B (2013), Series C (2016), Series D (2020), Series E (2024), Series E - II (2025) | 6 Series A, Series B (2013), Series C (2016), Series D (2020), Series E (2024), Series E - II (2025) | 6 Series A, Series B (2013), Series C (2016), Series D (2020), Series E (2024), Series E - II (2025) | ||
Board Seats | |||||
Type | Venture Capital | Corporate Venture | Venture Capital | Corporate Venture | Venture Capital |
Location | Pennsylvania | Switzerland | France | New York | United Kingdom |
Compare Mission Therapeutics to Competitors
Concept Life Sciences provides integrated drug discovery and development services across the pharmaceutical, biotechnology, and agricultural chemical industries. The company offers services including medicinal chemistry, biological assay development and screening, and toxicology assessments. Concept Life Sciences operates in various therapeutic areas such as immuno-oncology and neuroscience, and provides good manufacturing practice (GMP) manufacturing and analytical chemistry services. It was founded in 2014 and is based in Sandwich, United Kingdom.
Akamis Bio is a clinical-stage oncology company focused on tumor gene therapy within the healthcare sector. The company develops Tumor-Specific Immuno-Gene (T-SIGn4) therapeutics that deliver therapeutic proteins directly to solid tumors. Akamis Bio's T-SIGn4 platform is designed to remodel the tumor microenvironment. Akamis Bio was formerly known as PsiOxus Therapeutics. It was founded in 2010 and is based in Cambridge, Massachusetts.
BioAscent Discovery focuses on integrated drug discovery services within the pharmaceutical and biotechnology sectors. The company provides services such as assay development, target analysis, screening strategies, compound screening, medicinal and synthetic chemistry, computational chemistry, and compound management, supported by in-house diversity and fragment libraries. BioAscent serves clients in the pharmaceutical and biotechnology industries, facilitating drug discovery from assay development to preclinical and clinical candidate stages. BioAscent Discovery was formerly known as Caledonian Drug Discovery. It was founded in 2013 and is based in Lanarkshire, United Kingdom.
Domainex operates as a drug discovery service company within the pharmaceutical and biotechnology sectors. The company provides preclinical drug discovery services, including medicinal chemistry, structure-based and fragment-based drug design, computational chemistry, and assay development and screening. Domainex's services support various stages of drug discovery, from early-stage research to the identification and optimization of candidate drugs. It was founded in 2001 and is based in Essex, United Kingdom.
CellCentric is a clinical stage biotech company focused on developing p300/CBP inhibitors for cancer treatment. Its lead product, inobrodib, is an oral small molecule drug that inhibits the twin gene co-activation factors p300 and CBP. Inobrodib is being evaluated in clinical trials for its use against multiple myeloma and other specific cancer types. It was founded in 2003 and is based in Cambridge, England.
Sitryx is a biopharmaceutical company specializing in immunometabolism within the healthcare industry. The company develops therapeutics that regulate cell metabolism to treat autoimmune and inflammatory diseases. Sitryx's approach focuses on rebalancing the immune system and achieving disease remission. It was founded in 2018 and is based in Oxford, England.
Loading...